In this video interview, David Morton, PhD, director of biostatistics at Certara, outlines how increasing FDA support is helping drive adoption of Bayesian methods, particularly in rare disease and ...
In this video interview, David Morton, PhD, director of biostatistics at Certara, discusses how growing FDA support is accelerating the adoption of Bayesian approaches, enabling more flexible, ...
Abstract: Sparse diagnosis techniques for antenna arrays provide an efficient approach to fault diagnosis by leveraging the sparse nature of faulty elements. In practical scenarios, an unknown ...
Abstract: We conducted an in-depth investigation into the impact of Conditional Variational Autoencoders (CVAE) and Bayesian Neural Networks (BNN) on high dynamic range (HDR) image reconstruction. A ...
The FDA’s new draft guidance on Bayesian methods in clinical trials has been hailed by some as a breakthrough that could speed drug development. But statisticians and researchers are divided on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results